R Squared’s Aquestive Therapeutics AQST Stock Holding History

R Squared’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,010	Closed	-$3.6K	–	367
2024 Q4	$3.6K	Buy	+1,010	New	+$4.66K	﹤0.01%	1381

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

R Squared's AQST Position: Q1 2025 in Review

R Squared sold out of Aquestive Therapeutics (AQST) in Q1 2025, closing a stake of 1,010 shares — an estimated $3.6K sold.

R Squared first reported a position in AQST in Q4 2024 and held it in 1 quarter. The position peaked at $3.6K in Q4 2024. 121 funds tracked by Wall St. Rank hold AQST as of Q1 2025.

R Squared reported no remaining Aquestive Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,010 Aquestive Therapeutics shares in Q1 2025, an estimated $3.6K.
R Squared first reported a position in Aquestive Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Aquestive Therapeutics position peaked at $3.6K in Q4 2024.
121 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.